| Literature DB >> 31293974 |
Kerstin Jütten1,2, Verena Mainz2, Siegfried Gauggel2, Harshal Jayeshkumar Patel3,4, Ferdinand Binkofski3,4,5, Martin Wiesmann6, Hans Clusmann1, Chuh-Hyoun Na1.
Abstract
Immunohistochemical data based on isocitrate-dehydrogenase (IDH) mutation status have redefined glioma as a whole-brain disease, while occult tumor cell invasion along white matter fibers is inapparent in conventional magnetic resonance imaging (MRI). The functional and prognostic impact of focal glioma may however relate to the extent of white matter involvement. We used diffusion tensor imaging (DTI) to investigate microstructural characteristics of whole-brain normal-appearing white matter (NAWM) in relation to cognitive functions as potential surrogates for occult white matter involvement in glioma. Twenty patients (12 IDH-mutated) and 20 individually matched controls were preoperatively examined using DTI combined with a standardized neuropsychological examination. Tumor lesions including perifocal edema were masked, and fractional anisotropy (FA) as well as mean, radial, and axial diffusivity (MD, RD, and AD, respectively) of the remaining whole-brain NAWM were determined by using Tract-Based Spatial Statistics and histogram analyses. The relationship between extratumoral white matter integrity and cognitive performance was examined using partial correlation analyses controlling for age, education, and lesion volumes. In patients, mean FA and AD were decreased as compared to controls, which agrees with the notion of microstructural impairment of NAWM in glioma patients. Patients performed worse in all cognitive domains tested, and higher anisotropy and lower MD and RD values of NAWM were associated with better cognitive performance. In additional analyses, IDH-mutated and IDH-wildtype patients were compared. Patients with IDH-mutation showed higher FA, but lower MD, AD, and RD values as compared to IDH-wildtype patients, suggesting a better preserved microstructural integrity of NAWM, which may relate to a less infiltrative nature of IDH-mutated gliomas. Diffusion-based phenotyping and monitoring microstructural integrity of extratumoral whole-brain NAWM may aid in estimating occult white matter involvement and should be considered as a complementary biomarker in glioma.Entities:
Keywords: IDH mutation; diffusion tensor imaging; glioma; microstructural integrity; neuropsychology; normal-appearing white matter
Year: 2019 PMID: 31293974 PMCID: PMC6606770 DOI: 10.3389/fonc.2019.00536
Source DB: PubMed Journal: Front Oncol ISSN: 2234-943X Impact factor: 6.244
Clinical description of included patients.
| 1 | y | Astrocytoma | II | Temporal | r | 30 | y | n | 30–35 | 13 |
| 2 | y | Astrocytoma | II | Frontal | l | 51 | y | n | 20–25 | 16 |
| 3 | y | Astrocytoma | II | Parietal | l | 64 | y | n | 55–60 | 18 |
| 4 | y | Astrocytoma | II | Frontal | l | 158 | y | n | 26–30 | 13 |
| 5 | y | Oligodendro-glioma | II | Frontal | r | 2 | n | n | 36–40 | 13 |
| 6 | y | Oligodendro-glioma | II | Frontal | l | 22 | n | n | 26–30 | 13 |
| 7 | y | Anaplastic astrocytoma | III | Frontal | l | 21 | y | y | 50–55 | 13 |
| 8 | y | Anaplastic astrocytoma | III | Parietal | l | 119 | y | n | 20–25 | 13 |
| 9 | y | Anaplastic astrocytoma | III | Frontal | r | 155 | n | n | 30–35 | 15 |
| 10 | y | Anaplastic astrocytoma | III | Frontal, insular | r | 175 | y | y | 30–35 | 13 |
| 11 | y | Anaplastic oligodendro-glioma | III | Frontal | l | 39 | y | n | 50–55 | 15 |
| 12 | y | Anaplastic oligodendro-glioma | III | Frontal | r | 96 | n | n | 30–35 | 18 |
| 13 | n | Dysembryo-plastic neuroepithelial tumor | I | Hippocampal | l | 24 | y | n | 40–45 | 15 |
| 14 | n | Anaplastic astrocytoma | III | Temporo-parieto-occipital | l | 144 | n | n | 66–70 | 12 |
| 15 | n | Glioblastoma multiforme | IV | Fronto-temporal, insular | l | 204 | y | y | 60–65 | 15 |
| 16 | n | Glioblastoma multiforme | IV | Temporal, insular | l | 111 | y | n | 56–60 | 10 |
| 17 | n | Glioblastoma multiforme | IV | Fronto-temporal, insular | l | 145 | n | y | 66–70 | 9 |
| 18 | n | Glioblastoma multiforme | IV | Frontal | r | 182 | n | y | 50–55 | 12 |
| 19 | n | Glioblastoma multiforme | IV | Parietal, thalamic | l | 65 | y | y | 50–55 | 13 |
| 20 | – | Presumed low-grade glioma | – | Occipital | r | 1 | n | n | 60–65 | 12 |
IDH, isocitrate–dehydrogenase; y, yes; n, no; l, left; r, right; AE, anti-epileptics; m, male; f, female.
Recurrent glioblastoma 5 months after first tumor resection and adjuvant radiochemotherapy.
Patient refrained from surgery so that no histopathological confirmation could be obtained.
Years of education were computed by the sum of years spent for school career and further training/study.
Figure 1Example of a grade III tumor segmentation based on a fluid attenuation inversion recovery (FLAIR) image. Segmented tumor tissue (red) was excluded in both patients' diffusion weighted images (DWIs) as well as their matched controls' DWIs (black) prior to white matter (WM) skeleton extraction. Only those WM voxels revealing a fractional anisotropy (FA) value of 0.2 or higher were used to create a WM skeleton mask (orange), which was then applied to mean, radial, and axial diffusivity (MD, RD, and AD) maps. Mean (M) and peak width difference between the 95th and 5th percentile (PS) of each skeletonized diffusion parameter were computed by means of histogram analyses.
Figure 2Significant results of between-group and partial correlation analyses. Significant differences in fractional anisotropy (FA) and axial diffusivity (AD) as well as performance on the Verbal Learning and Memory Test (VLMT, VLMT_rec = number of words recalled) and the Trail-Making Test (TMT, TMT_RTexe = reaction times on differences between TMT parts A and B) are displayed in gray for the control group (CG) and black for patients (PAT) in the upper panel. All significant partial correlations (rpartial) between mean (M) and peak width of skeletonized (PS) FA, mean, radial, and axial diffusivity (MD, RD, and AD), and behavioral performance are visualized for patients in the lower panel. Significances for each analysis (N = number of subjects included) were computed at p < 0.05, including standardized effect sizes (ES) and confidence intervals (CI).
Results of group statistics on differences between patients and controls.
| CG ( | PAT ( | IDHmut ( | IDHwt ( | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FAM | 0.43 | 0.02 | 0.42 | 0.02 | 1.85 | 0.43 | 0.02 | 0.40 | 0.02 | −3.45 | – | |||||
| FAPS | 0.48 | 0.02 | 0.46 | 0.02 | 1.74 | 0.05 | −0.98 | [−1.64 to | 0.47 | 0.02 | 0.45 | 0.02 | −1.81 | 0.05 | −0.96 | [−1.94 |
| MDM | 0.79 | 0.02 | 0.79 | 0.03 | 0.05 | 0.48 | 0.00 | [−0.62 | 0.78 | 0.02 | 0.81 | 0.02 | 3.28 | |||
| MDPS | 0.29 | 0.05 | 0.32 | 0.06 | −1.39 | 0.09 | 0.53 | [−0.10 | 0.29 | 0.05 | 0.36 | 0.06 | 2.54 | |||
| RDM | 0.59 | 0.03 | 0.60 | 0.03 | −0.69 | 0.25 | 0.33 | [−0.33 | 0.58 | 0.03 | 0.62 | 0.03 | 3.55 | |||
| RDPS | 0.41 | 0.03 | 0.42 | 0.04 | −0.95 | 0.17 | 0.28 | [−0.35 | 0.41 | 0.02 | 0.45 | 0.04 | 2.60 | |||
| ADM | 1.18 | 0.02 | 1.17 | 0.02 | 2.01 | – | 1.16 | 0.02 | 1.18 | 0.02 | 2.02 | |||||
| ADPS | 0.75 | 0.04 | 0.74 | 0.05 | 0.67 | 0.25 | −0.22 | [−0.84 | 0.72 | 0.04 | 0.75 | 0.06 | 1.25 | 0.11 | 0.60 | [−0.35 |
| VLMT_rec | 57 | 8 | 47 | 14 | 2.65 | – | 51 | 11 | 35 | 16 | −2.35 | – | ||||
| VLMT_con | 1 | 2 | 2 | 2 | −1.32 | 0.10 | 0.50 | [−0.22 | 2 | 1 | 3 | 5 | 0.41 | 0.35 | 0.35 | [−0.82 |
| VLMT_recog | 14 | 1 | 12 | 2 | 1.61 | 0.06 | −1.04 | [−1.80 to | 13 | 2 | 11 | 2 | −2.24 | – | ||
| ANT_RTcor (ms) | 505 | 64 | 560 | 87 | −1.28 | 0.11 | 0.70 | [−0.06 | 546 | 75 | 613 | 123 | 1.21 | 0.13 | 0.73 | [−0.57 |
| ANT_F | 4 | 3 | 3 | 4 | 0.68 | 0.25 | −0.27 | [−1.01 | 3 | 4 | 2 | 1 | −0.45 | 0.33 | −0.27 | [−1.55 |
| TMT_RTexe (s) | 23 | 10 | 43 | 26 | −2.54 | 32 | 15 | 55 | 38 | 1.65 | 0.06 | 0.91 | [−0.30 | |||
DV, dependent variable; CG, control group; PAT, patient group; IDH, isocitrate–dehydrogenase; IDHmut, IDH-mutated glioma; IDHwt, IDH-wildtype glioma; N, number of included subjects; M, mean; SD, standard deviation; t, value of test statistic; p, significance; ES, effect size; CI, confidence interval; FA, fractional anisotropy; MD, mean diffusivity; RD, radial diffusivity; AD, axial diffusivity; PS, peak width difference of skeletonized diffusivity; VLMT, Verbal Learning and Memory Test; ANT, Attention Network Test; TMT, Trail-Making Test; VLMT_rec, recall; VLMT_con, consolidation; VLMT_recog, recognition; ANT_RTcor, reaction time of correct trials; ANT_F, number of errors; TMT_RTexe, difference in reaction time between TMT-A and TMT-B.
Significant results (p <0.05, one-tailed), ES, and CI are printed in bold.
Figure 3Group differences in diffusivity parameters depending on IDH-mutation status. Significant differences in fractional anisotropy (FA), mean diffusivity (MD), and radial diffusivity (RD) are displayed for patients with isocitrate–dehydrogenase (IDH)-mutation status (lined bar) and IDH-wildtype patients (dotted bar). Significances for each analysis (N = number of patients) were computed at p < 0.05, including standardized effect sizes (ES) and confidence intervals (CI).